solute carrier family 26 member 3Genealiases: CLD · DRA
Q-omics provides the consensus-scored SLC26A3 profile across patient tissues and cancer cell-line models. SLC26A3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, SLC26A3 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SLC26A3 RNA expression shows 15,918 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, COAD, and TGCT as cancer lineages where SLC26A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC26A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC26A3 survival associations across molecular data types. SLC26A3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC26A3 RNA expression–survival associations across cancer types. High SLC26A3 expression shows unfavorable associations in KIRC, UVM and LIHC, but favorable associations in SCLC, BLCA and COAD. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify SCLC as the clearest survival context for SLC26A3 RNA expression.
This table summarizes SLC26A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC26A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC26A3 shows lower tumor expression in COAD, THCA, READ, LUAD, BRCA and UCEC. The COAD box plot shows higher SLC26A3 RNA expression in normal versus tumor tissue (log2 FC = −5.959, t-test p < 0.001).
This table shows molecular features associated with SLC26A3 in patient tissues and cancer cell lines. In patient samples, SLC26A3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC26A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
